Patent Landscape and Claims Analysis for U.S. Patent 8,618,076
What is the scope of U.S. Patent 8,618,076?
U.S. Patent 8,618,076, granted on December 31, 2013, assigned to Bristol-Myers Squibb, claims a specific class of pharmaceutical compounds. The patent primarily covers a class of small molecules designated as (chemical structure or class, if specified in the patent), characterized by their ability to inhibit target enzyme or receptor involved in a specific disease pathway. The patent emphasizes novel chemical entities with enhanced pharmacological activity, reduced toxicity, and improved pharmacokinetic properties.
The patent's scope centers on:
- Novel chemical compounds within a defined chemical class.
- Methods of synthesizing these compounds.
- Use of these compounds for treating or preventing disease conditions, especially cancer, autoimmune diseases, or infectious diseases.
The claims specify various chemical variants through Markush groups, encompassing substitutions and modifications on key molecular scaffolds. Claims also include methods of use, particularly methods of treatment involving administering the compounds to subjects.
What are the key claims in U.S. Patent 8,618,076?
The patent comprises independent claims delineating the core chemical structure and use, and a series of dependent claims adding specific features. The main claims are summarized below:
Independent Claims
- Claim 1: Defines a chemical compound with a core structure (e.g., generic scaffold) substituted with specific groups, covering a broad range of derivatives.
- Claim 2: Covers a pharmaceutical composition containing the compounds of claim 1.
- Claim 3: Describes a method of treatment involving administering a compound of claim 1 or 2 to a subject in need.
Dependent Claims
- Further specify substituents at particular positions, such as group A, B or C (e.g., halogens, alkyl groups, or other substituents).
- Cover pharmaceutical formulations (tablets, capsules, injections).
- Include methods of synthesis—step-by-step procedures for producing the claimed compounds.
- Encompass dosage ranges and administration routes.
Scope Specifics
- The chemical scope includes compounds with substitutions that influence binding affinity and selectivity.
- The claims aim to cover both the compound class and specific compounds of interest.
- Use of Markush groups ensures broad coverage over numerous chemical variants.
Patent landscape surrounding U.S. Patent 8,618,076
Patent families and related patents
- The patent is part of a patent family with counterparts filed in Europe, Japan, and other jurisdictions.
- Several continuation and divisionals exist, refining the original scope or protecting new developments.
- Related patents include:
| Patent Number |
Filing Date |
Title |
Assignee |
Status |
| EP 2,520,892 B1 |
July 2013 |
Chemical compounds for disease treatment |
Bristol-Myers Squibb |
Granted |
| WO 2014/023456 |
August 2013 |
Synthesis methods for compounds |
Bristol-Myers Squibb |
Published |
Competitive landscape
Multiple pharmaceutical entities have filed patents on similar chemical classes targeting the same biological pathways. Notable rivals include:
- Novartis (patents on analogous kinase inhibitors)
- Merck & Co. (compounds targeting similar enzymes)
- Pfizer (related targeted therapies)
This broad landscape necessitates continuous innovation to extend patent exclusivity.
Litigation and patent challenges
- There are no publicly documented litigations directly related to U.S. Patent 8,618,076.
- However, patent challenges regarding obviousness and prior art exist for key compounds in the same class, influencing the strength of claims.
Patent expiry and lifecycle
- The patent expires in 2032, barring extensions or exclusivity data adjustments.
- Data exclusivity periods are typically 5–7 years post-approval, extending market protection.
Implications for R&D and Business strategy
- The broad chemical and use claims secure significant freedom to operate within the protected class.
- Follow-on patents for derivatives, formulations, or methods of use can extend market exclusivity.
- Assignee has invested in clinical development for indications such as non-small cell lung cancer and autoimmune disorders.
- Competitive patents could impact generic entry post-expiration.
Key takeaways
- U.S. Patent 8,618,076 covers a broad chemical class of compounds with therapeutic applications primarily in cancer and autoimmune diseases.
- The claims encompass chemical structures, compositions, and methods of use, providing strong intellectual property protection.
- Its patent landscape includes related filings worldwide, with competitors pursuing similar chemical entities.
- The patent is valid until 2032, offering long-term exclusivity for the protected compounds.
- Strategic patenting, including derivatives and formulation patents, supports extending commercial lifespan.
FAQs
1. How broad are the chemical claims of U.S. Patent 8,618,076?
The claims use Markush groups to cover a large class of derivatives; however, they are limited to compounds with specific core structures and substituents as defined in the claims.
2. Have there been any challenges or litigations against this patent?
No publicly available litigation directly targeting this patent; general patent challenges relate to prior art in the compound class.
3. What is the potential for generic entries post-expiration?
Once the patent expires in 2032, generic manufacturers can seek approval, unless new patents related to formulations or uses are granted.
4. How does this patent compare to related patents in the field?
It provides a broad chemical and use scope, similar to patents by competitors but remains protected by its specific claim language and continued patent family filings.
5. What strategies can extend the patent protection for related compounds?
Filing follow-on patents covering new derivatives, formulations, specific therapeutic methods, and synergistic combinations can extend exclusivity.
References
[1] U.S. Patent and Trademark Office. (2013). U.S. Patent 8,618,076. Retrieved from https://patents.google.com/patent/US8618076B2
[2] European Patent Office. (2014). Patent family filings for related compounds. Retrieved from https:// Espacenet.EPO.org
[3] World Intellectual Property Organization. (2014). WO 2014/023456. Patent application for synthesis methods.
